| PDF (450kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-335084
- DOI to cite this document:
- 10.5283/epub.33508
Abstract
Background Eczema is a common chronic or chronically relapsing, inflammatory skin disease that exerts a substantial negative impact on quality of life (QoL). The Harmonising Outcome Measures for Eczema (HOME) initiative has used a consensus-based process which identified QoL as one of the four core outcome domains to be assessed in all eczema clinical trials. A number of measurement instruments ...

Owner only: item control page